Clinical Development Research White Paper 
Conversations in Drug Development Trends
FEBRUARY 21, 2024
During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study. We recently published a white paper discussing the value of proactive AME studies, best practices, and lessons we’ve learned over the years to help optimize your study.
Conversations in Drug Development Trends
MARCH 7, 2024
Are there differential financial incentives to encourage sponsors to initiate early phase clinical research under a CTA, and how do those incentives compare to incentives that exist to initiate the same research under an IND? For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 11, 2020
Covid-19 command center aims to accelerate clinical research by individual sponsors to combat disease. The Covid-19 command center was created to provide sponsors of clinical trials pursuing in-house Covid-19 research with an AI-powered data analytics platform. Saama Technologies, Inc. ,
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and controls (CMC). By Holly N.
The Pharma Data
AUGUST 7, 2020
Most importantly, we are continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly Research Laboratories in a partnership with AbCellera.
Conversations in Drug Development Trends
JULY 29, 2024
Clinical development programs must acknowledge the complexity and variability of obesity as a condition. Partnering with a CRO that emphasizes the complexity of the patient’s voice and harnesses the nuances of clinical trial design is crucial for executing successful clinical research.
Conversations in Drug Development Trends
NOVEMBER 21, 2023
As a provider of end-to-end clinical development solutions, we plan to leverage our expertise to refine drug-disease matches identified by Every Cure’s use of AI and data analysis. At Worldwide, we deliver full-service clinical development to support drug approval and commercialization.
Expert insights. Personalized for you.
80 
Let's personalize your content